Corbus Pharmaceuticals (NASDAQ: CRBP) refreshes and furnishes new investor presentation

Rhea-AI Filing Summary

Corbus Pharmaceuticals Holdings, Inc. filed a current report to let investors know that management has updated the company’s investor presentation. The revised presentation is being used to describe its business and is furnished as Exhibit 99.1 to the report. The company notes that this material is being provided under a Regulation FD disclosure item, meaning it is intended to share information broadly with the market. The investor presentation and related materials are furnished rather than filed, so they are not automatically subject to certain liability provisions or incorporated into other securities filings unless specifically referenced.

8-K Event Classification

2 items: 7.01, 9.01

2 items

Item 7.01 Regulation FD Disclosure Disclosure

Material non-public information disclosed under Regulation Fair Disclosure, often investor presentations or guidance.

Item 9.01 Financial Statements and Exhibits Exhibits

Financial statements, pro forma financial information, and exhibit attachments filed with this report.

Understanding 8-K Material Events →

0001595097false00015950972026-01-122026-01-12

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): January 12, 2026

CORBUS PHARMACEUTICALS HOLDINGS, INC.

(Exact name of Registrant as Specified in Its Charter)

Delaware			001-37348	46-4348039
(State or Other Jurisdiction of Incorporation)			(Commission File Number)	(IRS Employer Identification No.)
500 River Ridge Drive
Norwood, Massachusetts				02062
(Address of Principal Executive Offices)				(Zip Code)

Registrant’s Telephone Number, Including Area Code: (617) 963-0100

Not Applicable

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
Common Stock, par value $0.0001 per share		CRBP		The Nasdaq Capital Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 7.01 Regulation FD Disclosure.

Corbus Pharmaceuticals Holdings, Inc. updated its presentation used by management to describe its business. A copy of the presentation is furnished as Exhibit 99.l and incorporated herein by reference.

The information in this Current Report on Form 8-K under Item 7.01, including the information contained in Exhibit 99.1, is being furnished to the Securities and Exchange Commission, and shall not be deemed to be “filed” for the purposes of Section 18 of the Exchange Act, or otherwise subject to the liabilities of that section, and shall not be deemed to be incorporated by reference into any filing under the Securities Act or the Exchange Act, except as shall be expressly set forth by a specific reference in such filing.

Item 9.01 Financial Statements and Exhibits.

(d) The following exhibit is furnished with this report:

Exhibit No.		Description
99.1		Investor Presentation
104		Cover Page Interactive Data File (embedded within the Inline XBRL document).

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

			Corbus Pharmaceuticals Holdings, Inc.
Date:	January 12, 2026	By:	/s/ Yuval Cohen
			Name: Yuval Cohen Title: Chief Executive Officer

FAQ

What did Corbus Pharmaceuticals (CRBP) disclose in this 8-K filing?

Corbus Pharmaceuticals disclosed that it updated the presentation used by management to describe its business, and furnished this updated investor presentation as Exhibit 99.1 under a Regulation FD disclosure item.

What is included as Exhibit 99.1 in Corbus Pharmaceuticals’ 8-K?

Exhibit 99.1 is an Investor Presentation that management uses to describe Corbus Pharmaceuticals’ business and has been furnished as part of this current report.

How is the updated Corbus Pharmaceuticals investor presentation treated under securities laws?

The information provided under Item 7.01, including Exhibit 99.1, is being furnished to the SEC and is not deemed to be “filed” for purposes of Section 18 of the Exchange Act or automatically incorporated by reference into other filings, except where expressly referenced.

Which exchange lists Corbus Pharmaceuticals’ common stock?

Corbus Pharmaceuticals’ common stock, par value $0.0001 per share, trades on The Nasdaq Capital Market under the symbol CRBP.

What is the purpose of the Regulation FD disclosure by Corbus Pharmaceuticals?

The Regulation FD disclosure is used to provide broad, non-selective access to the updated investor presentation so that all market participants receive the same business information at the same time.

Who signed the Corbus Pharmaceuticals 8-K related to the updated presentation?

The report was signed on behalf of Corbus Pharmaceuticals Holdings, Inc. by Yuval Cohen, who is identified as the company’s Chief Executive Officer.